Paul Lu
Director, Head of Business Development at RTW Investments
New York, New York
Overview
Work Experience
Managing Director, Head of Business Development
2020 - Current
I help drive partnering, business development, and strategic transactions for RTW and our internally incubated portfolio companies.
RTW Investments makes investments in forward-thinking healthcare companies.
Global Head, Business Development & Alliances
2019 - 2020
Responsible for expanding innovative pipeline through partnerships and growing ex-Asia footprint. Hansoh Pharma (3692:HK) is a leading biopharmaceutical company in China committed to discovering and developing life-changing medicines to help patients conquer serious diseases and disorders. Hansoh Pharma has over 9,000 dedicated employees in China and the United States. With an equity value of approximately $35B, Hansoh is the 2nd largest biopharmaceutical companies in China and 6th largest in Asia by market capitalization. Founded in 1995, Hansoh has fully integrated research and development, manufacturing, and commercial capabilities, supporting a leadership position in oncology, central nervous system (CNS), anti-infectives, gastrointestinal disorders, diabetes, and autoimmune diseases, among others. With 1,400 professionals across R&D, Hansoh has developed several internally discovered drug candidates into NMPA-approved innovative medicines, including morinidazole, a third-generation nitroimidazole antibiotic; PEG-loxenatide, the first once-weekly long-acting GLP-1 analogue discovered and developed in China for the treatment of diabetes; flumatinib, a second-generation BCR-ABL inhibitor for frontline treatment of chronic myeloid leukemia; and almonertinib, a third-generation EGFR inhibitor for the treatment of NSCLC.
Founding Member
2019 - 2020
Founded and built Hansoh Bio, a U.S.-based biotech subsidiary of Hansoh Pharma, as its first employee. Launched Rockville Innovations Center, located in Maryland, focused on conducting first-in-class and best-in-class therapeutics discovery and development, with 30+ FTEs across functional teams including Fundamental Research, Biotherapeutics, Chemistry, Structural Biology & Biophysics, Business Development, and Operations. Created a strategic roadmap for Hansoh Bio and responsible for all talent acquisition, day-to-day operations, finance, budgeting, and administrative functions.
U.S. Head, Global Business Development
2017 - 2019
Led Global Business Development at Hengrui Medicine, overseeing licensing, alliances, M&A, and strategic investments. Established in 1970, Hengrui Medicine (SHA: 600276), is the largest and a leading biopharmaceutical company based in China devoted to empowering healthier lives through research, with capabilities across oncology, immunology, anesthesiology, cardiovascular diseases, metabolic diseases, and pain management.
Investment Banking - Mergers & Acquisitions
2013 - 2017
Advised pharmaceutical, biotech, and healthcare services companies as a member of Lazard’s healthcare investment banking group, executing complex M&A transactions, involving cross-border, shareholder activism, and restructuring situations. Founded in 1848, Lazard, one of the world's preeminent financial advisory and asset management firms, provides advice on mergers and acquisitions, strategic matters, restructuring, capital structure, and corporate finance to corporations and sovereign institutions globally.
Lazard is a financial advisory and asset management firm focused on income strategies, alternative investments, and private equity funds.
Raised $400,000,000.00.
Co-founder & President
2010 - 2012
The Biotechnology and Life Sciences Advising Group (BALSA) provide clients with data-driven consulting solutions to promote sustained growth of emerging technologies and scalable business.
The BALSA Group is a nonprofit organization that offers consulting solutions to promote emerging technologies and businesses.